Aaron Tallent

#quoteoftheday: "God may laugh, but I still have my plans." - Octavio (Gael Garcia Bernal) "Amores Perros" @GaelGarciaB

“You can write with the TV on and constantly check your email or messaging apps. It is just going to take you twice as long…” Three tips for getting into a better writing headspace:bit.ly/4vi0DqX

People living with HIV face higher risks of depression, suicide, and death. New studies show both medical and social factors play a major role. @IDSE_Online “Many people with HIV have experienced trauma…” bit.ly/3O6BE9M

Dalbavancin isn’t superior, but it may still shift treatment. New data show it’s as effective as standard therapy for S. aureus bacteremia, with easier administration. “Just as good and a lot easier to administer.” @IDSE_Online bit.ly/4maJVGu

Best news I've heard today.

Most writers have been getting this wrong. On April 24, the @APStylebook announced that it is updating its style guide to clarify that ‘healthcare’ should be written as one word and not as ‘health care.’ Read more: bit.ly/3QIuJVl

Simplifying HIV treatment may improve adherence and quality of life. New studies show single-tablet regimens can maintain effectiveness while reducing complexity. “Reducing the pill burden… is of paramount importance.” @IDSE_Online bit.ly/4sOcJXL

Radiation oncology may be stabilizing. Nearly 98% of PGY-2 positions were filled in this year’s Match—showing consistency after years of swings. “That consistency is encouraging.” @OncNewsCentral bit.ly/4dwqHcd

Cancer innovation starts with people. @ConquerCancerFd has spent decades funding researchers whose early work has led to breakthroughs in care. “We are not only investing in their ideas, but we are also investing in their careers.” Said Eileen Melnick bit.ly/4bPb8uX

Cancer research has changed dramatically over the last 40 years. From supercomputers to AI and multiomic analysis, researchers can now explore cancer in ways that weren’t possible before. “The technological advances… have been enormous.” @JCO_ASCO bit.ly/4ck7Dwy

AI, liquid biopsies, and computational oncology are changing how cancer is detected and treated. New research highlights how these tools are already being applied in real-world care. “We envision a future of increasingly proactive …” bit.ly/48j5C19 @ConquerCancerFd

That one can excuse or ignore this while claiming to be “pro-life” is a sign of a seared conscience. God have mercy on us all.

Exclamation points are everywhere, but that doesn’t mean they should be. Used well, they add energy. Overused, they can weaken your writing and make it feel less intentional. Read more: bit.ly/4cx3oNl

Not sure if anyone is having any trouble with @BassMagOnline, but their password reset function doesn't work and they don't respond when their subscribers contact them. Would hold off on subscribing from them.

New animal-model research is offering clues into why outcomes in recent mpox outbreaks may differ from earlier ones, and why certain variants behave very differently once they infect a host. bit.ly/4pCX5ga

A new declaration from African cancer experts is calling attention to a gap that has long limited both patient care on the continent and global understanding of how cancer develops, mutates, and presents across populations. bit.ly/4pIocqr

Reading shapes how we write. Stephen King calls it “the creative center of a writer’s life.” I logged everything I read last year, and only a handful of books truly earned five stars. Here’s what made the list.bit.ly/4jAQtgq

Updated IDSA guidelines are challenging long-held assumptions about when treatment is actually necessary for one of the most common fungal infections in the U.S., especially in regions where exposure is routine and often overlooked. #IDSA bit.ly/4oZBDkl

As private equity continues to move deeper into community oncology, new research is prompting tougher questions about what consolidation means for patients, pricing, and access, particularly in lower-income and underserved areas.bit.ly/45bi3up

New phase 3 data presented at #SABCS is raising questions about whether a novel endocrine therapy could alter the standard approach for ER-positive, HER2-negative disease. bit.ly/3XWnhXa

Results from a large phase 3 trial presented at #SABCS are prompting oncologists to rethink what maintenance therapy can look like after induction chemotherapy. bit.ly/4aNL4Qv